Literature DB >> 12209494

What do we know about lupus membranous nephropathy? An analytic review.

Sharon L Kolasinski1, James B Chung, Daniel A Albert.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 12209494     DOI： 10.1002/art.10417

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  4 in total

1.  Prognosis of lupus membranous nephropathy in children.

Authors:  Sylvie Nathanson; Rémi Salomon; Bruno Ranchin; Marie-Alice Macher; Marie-Pierre Lavocat; Marie-Jeanne Krier; Véronique Baudouin; Christine Azéma; Brigitte Bader-Meunier; Georges Deschênes
Journal:  Pediatr Nephrol       Date:  2006-06-30       Impact factor: 3.714

2.  Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria.

Authors:  Eduardo F Borba; Lissiane K Guedes; Romy B Christmann; Camille P Figueiredo; Célio R Gonçalves; Eloisa Bonfá
Journal:  Rheumatol Int       Date:  2006-05-31       Impact factor: 2.631

3.  Lupus nephritis: current issues.

Authors:  C P Mavragani; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

4.  Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy.

Authors:  Matthew Baker; Yashaar Chaichian; Mark Genovese; Vimal Derebail; Panduranga Rao; Winn Chatham; Michael Bubb; Sam Lim; Hooman Hajian; Oksana Gurtovaya; Uptal Patel; James Tumlin
Journal:  RMD Open       Date:  2020-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.